Triphenylethylene SERM. Tissue-selective ER agonism/antagonism: antagonist in breast (anti-proliferative, primary indication), partial agonist in bone (protective) + endometrium (hyperplasia / cancer risk) + liver (lipid + clotting-factor effects). Activity driven primarily by the CYP2D6-derived metabolite endoxifen (~100× ER affinity vs parent). In men: blocks hypothalamic ER-mediated negative feedback → raises LH/FSH → testicular testosterone — rationale for PCT after AAS cycles and off-label treatment of gynaecomastia.
Half-Life & Elimination Curve (PO: 4d)
Plasma (PO)t½ Decay (4d)Effect Site (ke0)
0×t½0h100%(13.9 µg/L)
1×t½4d50%(6.95 µg/L)
2×t½8d25%(3.47 µg/L)
3×t½12d12.5%(1.74 µg/L)
4×t½16d6.3%(0.868 µg/L)
5×t½20d3.1%(0.434 µg/L)
Elimination t½4d (PO)
Rate Constant (ke)0.00722 h⁻¹
Time to Peak (Tmax)3.85h
Est. Peak (Cmax)13.9 µg/L
Clearance (CL)10.1 L/h
97% Washout (5×t½)20d
Dosing Guidelines
Oral (PO): Typical 20 mg (Range: 10–40 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 100% · Volume of Distribution (Vd): 1400 L · Absorption (ka): 1.37 h⁻¹ (t½ka ≈ 30m) [PMID 7427960]
Clomiphene (caution): both SERMs with overlapping ER modulation — combination not standard; clomiphene's hypothalamic-axis effects may complicate breast cancer ER blockade